Pharmacokinetics and pharmacogenomics for 13-cis retinoic acid in neuroblastoma
Pharmacokinetics and pharmacogenomics for 13-cis retinoic acid in neuroblastoma
批准号:
9143716
负责人:
Min Hee Kang
金额:
$28.41万
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-08-01 至 2018-07-31
关键词:
AffectAgeAntibodiesAutologousBiological AssayBlood drug level resultCell ExtractsCell LineCellsChildClinicalClinical ResearchClinical TrialsCollaborationsDataDifferentiation InducerDisease-Free SurvivalDoseDown-RegulationDrug KineticsDrug TargetingDrug usageEnrollmentEnzymesFoodFormulationFutureGeneric DrugsGeneticGenetic MarkersGenetic PolymorphismGenomic DNAGenotypeGoalsHealthHematopoietic Stem Cell TransplantationHigh Pressure Liquid ChromatographyHumanImmunotherapyIn VitroInhibition of Cell ProliferationIsotretinoinLaboratoriesLiver MicrosomesMYCN geneMalignant Childhood NeoplasmMetabolic PathwayMetabolismMethodsMonoclonal Antibody Ch14.18N-Myc ProteinN-methylacetamide-oxotremorine MNeuroblastomaOncogenesOutcomeParentsPathway interactionsPatientsPediatric Oncology GroupPharmaceutical PreparationsPharmacogenomicsPharmacologyPhasePhase III Clinical TrialsPhysiologic pulsePlasmaPlasma CellsRecommendationRecurrenceRecurrent diseaseResearch PersonnelResidual NeoplasmRetinoidsRoleSamplingSignal TransductionSiteSympathetic Nervous SystemSystemTherapeutic EffectTreatment outcomeVariantVitamin Abasecancer cellcapsulecohortcytokinedrug metabolismhigh riskimprovedmass spectrometermetabolic profileneuroblastoma cellnovelpreclinical studypreventresearch studyresponsescreeningstandard of caresystemic toxicitytandem mass spectrometrytherapy outcome
中文摘要
描述(申请人提供):神经母细胞瘤是儿童交感神经系统的恶性肿瘤。13-顺式维甲酸(13-顺式ra)可诱导人神经母细胞瘤细胞分化,高剂量、脉冲13-顺式ra治疗可显著提高高危神经母细胞瘤患者的总生存率,但许多儿童在13-顺式ra治疗期间或治疗后出现复发。作为儿童肿瘤组(COG)的类维生素a药理学实验室,我们一直在收集神经母细胞瘤(A-3973, ANBL0532, ANBL0032和ANBL0931)的多个III期临床试验的血浆样本和细胞颗粒。出乎意料的是,在370名患者中,95%的患者达到了临床前研究预测的13-顺式ra浓度(< 5 μ M),而13-顺式ra代谢物4-氧-13-顺式ra在约44%的患者中为5 μ M。其他研究者推测,4-氧-13-顺- ra是一种无活性代谢物,一些人建议调节13-顺- ra的代谢,以防止药物转化为4-氧-13-顺- ra,从而潜在地提高药物的临床活性
英文摘要
DESCRIPTION (provided by applicant): Neuroblastoma is a malignant childhood tumor of the sympathetic nervous system. 13-cis retinoic acid (13- cis-RA) induces differentiation of human neuroblastoma cells, and high-dose, pulse 13-cis-RA treatment significantly improves overall survival of high-risk neuroblastoma patients, but many children develop recurrent disease during or after 13-cis-RA treatment. As the retinoid pharmacology laboratory for the Children's Oncology Group (COG), we have been collecting plasma samples and cell pellets from multiple phase III clinical trials of neuroblastoma (A-3973, ANBL0532, ANBL0032, and ANBL0931). Unexpectedly, 95% of 370 patients achieved concentrations (< 5 �M) of 13-cis-RA predicted to be subtherapeutic by preclinical studies, while the 13-cis-RA metabolite 4-oxo-13-cis-RA was e 5 �M in about 44% of patients. Other investigators have speculated that 4-oxo-13-cis-RA is an inactive metabolite and some have suggested modulation of 13-cis-RA metabolism to prevent transformation of the drug into 4-oxo-13-cis-RA to potentially improve the clinical activity of the
drug. By contrast, our preliminary experiments revealed that 4-oxo-13-cis- RA is as active as the parent drug in activation of retinoid signaling, inhibition of cell proliferation, and MYCN down-regulation in neuroblastoma cells. These novel observations led to our hypotheses that: 1) Achieving a plasma concentration of e 5 �M 13-cis-RA and/or 4-oxo-13-cis-RA is an important determinant of treatment outcome of 13-cis-RA. 2) 13-cis-RA pharmacokinetic (PK) variations seen in patients are associated with enzymatic polymorphisms (pharmacogenomics: PG). 3) Treatment outcomes will define the role of PG information and validate target levels of 13-cis-RA and/or 4-oxo-13-cis-RA, enabling future PK/PG-guided dosing of 13-cis-RA. Systemic toxicities of 13-cis-RA are favorable to entertaining future dose-adjustment studies, especially if
currently presumed target drug levels could be validated by clinical outcome data so that PK/PG data can be used to determine optimal dosing for low drug level (subtherapeutic) and very high drug level (possible systemic toxicity) patient cohorts. We propose 1) to study pharmacokinetic and metabolic profiling of 13-cis-RA in samples from 600 high-risk neuroblastoma patients enrolled in phase III clinical trials; 2) to determine PG of enzymatic polymorphisms using rapid throughput screening methods requiring minimal amounts of gDNA samples of neuroblastoma patients; 3) and to demonstrate that PK and/or PG for 13-cis- RA correlates with clinical outcomes for neuroblastoma patients undergoing 13-cis-RA treatment. This proposed study will potentially define PK and/or PG parameters that can be used to optimize dosing of 13- cis-RA in high-risk neuroblastoma patients.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
Cytotoxic activity of difluoromethylornithine compared with fenretinide in neuroblastoma cell lines.
在神经母细胞瘤细胞系中,二氟甲基鸟氨酸与芬维A胺的细胞毒性活性比较。
DOI:
10.1002/pbc.27447
发表时间:
2018
期刊:
Pediatric blood & cancer
影响因子:
3.2
作者:
[Makena,MonishR, Cho,HwangEui, Nguyen,ThinhH, Koneru,Balakrishna, Verlekar,DatteshU, Hindle,Ashly, Kang,MinH, Reynolds,CPatrick]
通讯作者:
Reynolds,CPatrick
MYC activation in tumor progression of neuroblastoma
-
批准号:10323261
-
项目类别:
-
资助金额:$36.56万
-
财政年份:2019
-
负责人:Min Hee Kang
-
依托单位:
MYC activation in tumor progression of neuroblastoma
-
批准号:10555259
-
项目类别:
-
资助金额:$36.56万
-
财政年份:2019
-
负责人:Min Hee Kang
-
依托单位:
MYC activation in tumor progression of neuroblastoma
-
批准号:10064998
-
项目类别:
-
资助金额:$38.81万
-
财政年份:2019
-
负责人:Min Hee Kang
-
依托单位:
Pharmacokinetics and pharmacogenomics for 13-cis retinoic acid in neuroblastoma
-
批准号:8501847
-
项目类别:
-
资助金额:$28.41万
-
财政年份:2013
-
负责人:Min Hee Kang
-
依托单位:
Pharmacokinetics and pharmacogenomics for 13-cis retinoic acid in neuroblastoma
-
批准号:8664817
-
项目类别:
-
资助金额:$27.55万
-
财政年份:2013
-
负责人:Min Hee Kang
-
依托单位:
Altered Glycolytic Pathway in in vitro Models of leukemia developed in hypoxia
-
批准号:8100621
-
项目类别:
-
资助金额:$44.44万
-
财政年份:2011
-
负责人:Min Hee Kang
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: